Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.56+0.05 (+0.67%)
Close on Nov 20, 2026Market cap $43.72MP/E –Yield –
Xilio Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Xilio Therapeutics
Xilio Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?